{"name":"Allergan","slug":"allergan","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":5300000000,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[{"name":"Botox","genericName":"ONABOTULINUMTOXINA","slug":"onabotulinumtoxina","revenue":5300000000,"yoyGrowth":0,"percentOfTotal":100}],"timeline":[{"date":"1954-01-01","label":"Bromanautine first approved","drug":"Bromanautine","drugSlug":"bromazine","type":"approval","sentiment":"positive"},{"date":"1978-01-01","label":"GoodSense Eye Drops Advanced Relief Moisturizer first approved","drug":"GoodSense Eye Drops Advanced Relief Moisturizer","drugSlug":"dextran","type":"approval","sentiment":"positive"},{"date":"2004-01-01","label":"Campral first approved","drug":"Campral","drugSlug":"acamprosate","type":"approval","sentiment":"positive"},{"date":"2006-01-01","label":"olopatadine 0.2% ophthalmic solution first approved","drug":"olopatadine 0.2% ophthalmic solution","drugSlug":"olopatadine-0-2-ophthalmic-solution","type":"approval","sentiment":"positive"},{"date":"2010-01-01","label":"Botox first approved","drug":"Botox","drugSlug":"onabotulinumtoxina","type":"approval","sentiment":"positive"},{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-09-30","label":"Bystolic Phase 3 readout (ANOCA - Angina With Non-obstructive Coronary Arteries, Coronary Microvascular Dysfunction (CMD))","drug":"Bystolic","drugSlug":"nebivolol","type":"phase3_readout","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Neuroscience","slug":"neuroscience","revenue":5300000000,"percentOfTotal":100,"drugCount":5,"colorKey":"oncology","drugs":[{"name":"Botox","genericName":"ONABOTULINUMTOXINA","slug":"onabotulinumtoxina","indication":"Overactive Bladder","status":"marketed","revenue":5300000000},{"name":"Vehicle to AGN-199201","genericName":"Vehicle to AGN-199201","slug":"vehicle-to-agn-199201","indication":"Neuropathic pain","status":"phase_3"},{"name":"Botulinum Toxin Type A 900kD","genericName":"Botulinum Toxin Type A 900kD","slug":"botulinum-toxin-type-a-900kd","indication":"Cervical dystonia","status":"marketed"},{"name":"Botulinum Toxin Type A 900kDa","genericName":"Botulinum Toxin Type A 900kDa","slug":"botulinum-toxin-type-a-900kda","indication":"Cervical dystonia","status":"marketed"},{"name":"Placebo-matching Ubrogepant","genericName":"Placebo-matching Ubrogepant","slug":"placebo-matching-ubrogepant","indication":"Acute treatment of migraine attacks with or without aura","status":"phase_3"}]},{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":68,"colorKey":"cardiovascular","drugs":[{"name":"AGN211745","genericName":"AGN211745","slug":"agn211745","indication":"Other","status":"phase_1"},{"name":"BELKYRA®","genericName":"BELKYRA®","slug":"belkyra","indication":"Other","status":"marketed"},{"name":"Betaprone","genericName":"PROPIOLACTONE","slug":"propiolactone","indication":"Antiseptic preparation","status":"marketed"},{"name":"Campral","genericName":"ACAMPROSATE","slug":"acamprosate","indication":"Alcoholism","status":"marketed"},{"name":"travoprost 0.004%","genericName":"travoprost 0.004%","slug":"travoprost-0-004","indication":"Other","status":"marketed"},{"name":"0.15% Brimonidine Tartrate","genericName":"0.15% Brimonidine Tartrate","slug":"0-15-brimonidine-tartrate","indication":"Other","status":"marketed"},{"name":"AGN-150998","genericName":"AGN-150998","slug":"agn-150998","indication":"Other","status":"phase_2"},{"name":"AGN-190168 Formulation 1","genericName":"AGN-190168 Formulation 1","slug":"agn-190168-formulation-1","indication":"Other","status":"phase_1"},{"name":"AGN-190168 Formulation 2","genericName":"AGN-190168 Formulation 2","slug":"agn-190168-formulation-2","indication":"Other","status":"phase_1"},{"name":"AGN-190584","genericName":"AGN-190584","slug":"agn-190584","indication":"Other","status":"marketed"},{"name":"AGN-195263 0.01%","genericName":"AGN-195263 0.01%","slug":"agn-195263-0-01","indication":"Other","status":"phase_2"},{"name":"AGN-199201","genericName":"AGN-199201","slug":"agn-199201","indication":"Muscle wasting and weakness in aging males","status":"phase_3"},{"name":"AGN-199201 Dose A","genericName":"AGN-199201 Dose A","slug":"agn-199201-dose-a","indication":"Muscle wasting or sarcopenia (phase 2 development)","status":"phase_2"},{"name":"AGN-199201 Dose B","genericName":"AGN-199201 Dose B","slug":"agn-199201-dose-b","indication":"Other","status":"phase_2"},{"name":"AGN-199201 Dose C","genericName":"AGN-199201 Dose C","slug":"agn-199201-dose-c","indication":"Phase 2 clinical trials for AGN-199201 Dose C are ongoing, but no specific indications have been reported.","status":"phase_2"},{"name":"AGN-199201 Formulation A","genericName":"AGN-199201 Formulation A","slug":"agn-199201-formulation-a","indication":"Other","status":"phase_1"},{"name":"AGN-199201 Formulation B","genericName":"AGN-199201 Formulation B","slug":"agn-199201-formulation-b","indication":"Other","status":"phase_1"},{"name":"AGN-199201 Formulation C","genericName":"AGN-199201 Formulation C","slug":"agn-199201-formulation-c","indication":"Other","status":"phase_1"},{"name":"AGN-210669 ophthalmic solution, 0.025%","genericName":"AGN-210669 ophthalmic solution, 0.025%","slug":"agn-210669-ophthalmic-solution-0-025","indication":"Other","status":"phase_1"},{"name":"AGN-210669 ophthalmic solution, 0.075%","genericName":"AGN-210669 ophthalmic solution, 0.075%","slug":"agn-210669-ophthalmic-solution-0-075","indication":"Other","status":"phase_2"},{"name":"AGN-210961 Formulation 2","genericName":"AGN-210961 Formulation 2","slug":"agn-210961-formulation-2","indication":"Other","status":"phase_2"},{"name":"AGN-210961 Formulation 3","genericName":"AGN-210961 Formulation 3","slug":"agn-210961-formulation-3","indication":"Other","status":"phase_2"},{"name":"AGN-210961 Formulation 4","genericName":"AGN-210961 Formulation 4","slug":"agn-210961-formulation-4","indication":"Other","status":"phase_2"},{"name":"AGN-210961 Formulation 6","genericName":"AGN-210961 Formulation 6","slug":"agn-210961-formulation-6","indication":"Muscle wasting or sarcopenia (investigational)","status":"phase_2"},{"name":"AGN-223575 Formulation A","genericName":"AGN-223575 Formulation A","slug":"agn-223575-formulation-a","indication":"Other","status":"phase_1"},{"name":"AGN-223575 Formulation B","genericName":"AGN-223575 Formulation B","slug":"agn-223575-formulation-b","indication":"Other","status":"phase_1"},{"name":"AGN-223575 Formulation C","genericName":"AGN-223575 Formulation C","slug":"agn-223575-formulation-c","indication":"Other","status":"phase_1"},{"name":"AGN-232411","genericName":"AGN-232411","slug":"agn-232411","indication":"Other","status":"phase_1"},{"name":"AGN208397 intravitreal injection","genericName":"AGN208397 intravitreal injection","slug":"agn208397-intravitreal-injection","indication":"Other","status":"phase_1"},{"name":"Alcaftadine 0.25%","genericName":"Alcaftadine 0.25%","slug":"alcaftadine-0-25","indication":"Other","status":"marketed"},{"name":"Alcaftadine Ophthalmic Solution 0.25%","genericName":"Alcaftadine Ophthalmic Solution 0.25%","slug":"alcaftadine-ophthalmic-solution-0-25","indication":"Allergic conjunctivitis","status":"phase_2"},{"name":"Androderm®","genericName":"Androderm®","slug":"androderm","indication":"Testosterone replacement therapy in adult males with primary or secondary hypogonadism","status":"marketed"},{"name":"Any Fixed Combination Therapy","genericName":"Any Fixed Combination Therapy","slug":"any-fixed-combination-therapy","indication":"Various conditions","status":"phase_2"},{"name":"BOTOX® purified neurotoxin complex","genericName":"BOTOX® purified neurotoxin complex","slug":"botox-purified-neurotoxin-complex","indication":"blepharospasm","status":"phase_2"},{"name":"Bimatoprost Ophthalmic Solution 0.01%","genericName":"Bimatoprost Ophthalmic Solution 0.01%","slug":"bimatoprost-ophthalmic-solution-0-01","indication":"Other","status":"marketed"},{"name":"Botox placebo (normal saline)","genericName":"Botox placebo (normal saline)","slug":"botox-placebo-normal-saline","indication":"Placebo control in Botox clinical trials (Phase 3)","status":"phase_3"},{"name":"Botulinum Toxin Type A 150kDa","genericName":"Botulinum Toxin Type A 150kDa","slug":"botulinum-toxin-type-a-150kda","indication":"Other","status":"marketed"},{"name":"Brimo PS DDS®","genericName":"Brimo PS DDS®","slug":"brimo-ps-dds","indication":"Treatment of hypogonadism in adult males","status":"phase_2"},{"name":"Brimonidine 0.2% ophthalmic solution","genericName":"Brimonidine 0.2% ophthalmic solution","slug":"brimonidine-0-2-ophthalmic-solution","indication":"Other","status":"marketed"},{"name":"Bromanautine","genericName":"bromazine","slug":"bromazine","indication":"Common cold","status":"marketed"},{"name":"Carboxymethylcellulose sodium and Glycerin","genericName":"Carboxymethylcellulose sodium and Glycerin","slug":"carboxymethylcellulose-sodium-and-glycerin","indication":"Other","status":"marketed"},{"name":"Cyclosporine 0.010% eye drops","genericName":"Cyclosporine 0.010% eye drops","slug":"cyclosporine-0-010-eye-drops","indication":"Prevention of organ rejection in transplant patients","status":"phase_2"},{"name":"Dexamethasone intravitreal implant","genericName":"Dexamethasone intravitreal implant","slug":"dexamethasone-intravitreal-implant","indication":"Other","status":"marketed"},{"name":"Formulation C: OnabotulinumtoxinA","genericName":"Formulation C: OnabotulinumtoxinA","slug":"formulation-c-onabotulinumtoxina","indication":"Blepharospasm","status":"phase_2"},{"name":"Ganforti","genericName":"Ganforti","slug":"ganforti","indication":"Other","status":"phase_2"},{"name":"IV Placebo (Saline)","genericName":"IV Placebo (Saline)","slug":"iv-placebo-saline","indication":"Clinical trial control / placebo comparator (not a therapeutic indication)","status":"marketed"},{"name":"Oxymetazoline HCL Cream 1.0%","genericName":"Oxymetazoline HCL Cream 1.0%","slug":"oxymetazoline-hcl-cream-1-0","indication":"Persistent facial erythema associated with rosacea","status":"marketed"},{"name":"Ulipristal acetate (UPA)","genericName":"Ulipristal acetate (UPA)","slug":"ulipristal-acetate-upa","indication":"Emergency contraception","status":"phase_3"},{"name":"Vehicle to Oxymetazoline HCL Cream","genericName":"Vehicle to Oxymetazoline HCL Cream","slug":"vehicle-to-oxymetazoline-hcl-cream","indication":"Persistent facial erythema associated with rosacea","status":"phase_3"},{"name":"alcaftadine 0.25% ophthalmic solution","genericName":"alcaftadine 0.25% ophthalmic solution","slug":"alcaftadine-0-25-ophthalmic-solution","indication":"Allergic conjunctivitis (itching associated with allergic conjunctivitis)","status":"marketed"},{"name":"bimatoprost 0.01% ophthalmic solution","genericName":"bimatoprost 0.01% ophthalmic solution","slug":"bimatoprost-0-01-ophthalmic-solution","indication":"Other","status":"marketed"},{"name":"bimatoprost 0.03% eye drops","genericName":"bimatoprost 0.03% eye drops","slug":"bimatoprost-0-03-eye-drops","indication":"Other","status":"marketed"},{"name":"bimatoprost 0.03% plus timolol 0.5%","genericName":"bimatoprost 0.03% plus timolol 0.5%","slug":"bimatoprost-0-03-plus-timolol-0-5","indication":"Other","status":"marketed"},{"name":"bimatoprost ophthalmic solution 0.03%","genericName":"bimatoprost ophthalmic solution 0.03%","slug":"bimatoprost-ophthalmic-solution-0-03","indication":"Other","status":"marketed"},{"name":"botulinum toxin Type A (12 U)","genericName":"botulinum toxin Type A (12 U)","slug":"botulinum-toxin-type-a-12-u","indication":"Other","status":"phase_3"},{"name":"botulinum toxin Type A (24 U)","genericName":"botulinum toxin Type A (24 U)","slug":"botulinum-toxin-type-a-24-u","indication":"Focal spasticity in patients with upper limb spasticity due to stroke or cerebral palsy","status":"phase_3"},{"name":"botulinum toxin Type A (300U)","genericName":"botulinum toxin Type A (300U)","slug":"botulinum-toxin-type-a-300u","indication":"Other","status":"phase_3"},{"name":"botulinum toxin Type A (44U)","genericName":"botulinum toxin Type A (44U)","slug":"botulinum-toxin-type-a-44u","indication":"Focal spasticity in patients with upper limb spasticity due to stroke or cerebral palsy","status":"phase_3"},{"name":"cyclosporine 0.05% ophthalmic emulsion","genericName":"cyclosporine 0.05% ophthalmic emulsion","slug":"cyclosporine-0-05-ophthalmic-emulsion","indication":"Other","status":"marketed"},{"name":"latanoprost 0.005%","genericName":"latanoprost 0.005%","slug":"latanoprost-0-005","indication":"Other","status":"marketed"},{"name":"latanoprost 0.005% eye drops","genericName":"latanoprost 0.005% eye drops","slug":"latanoprost-0-005-eye-drops","indication":"Other","status":"marketed"},{"name":"minoxidil 2% solution","genericName":"minoxidil 2% solution","slug":"minoxidil-2-solution","indication":"Other","status":"marketed"},{"name":"olopatadine 0.2% ophthalmic solution","genericName":"olopatadine 0.2% ophthalmic solution","slug":"olopatadine-0-2-ophthalmic-solution","indication":"Allergic conjunctivitis (ocular itching associated with allergies)","status":"marketed"},{"name":"onabotulinumtoxinA 24 U","genericName":"onabotulinumtoxinA 24 U","slug":"onabotulinumtoxina-24-u","indication":"Other","status":"phase_3"},{"name":"onabotulinumtoxinA 44 U","genericName":"onabotulinumtoxinA 44 U","slug":"onabotulinumtoxina-44-u","indication":"Blepharospasm","status":"phase_3"},{"name":"oxybutynin IR","genericName":"oxybutynin IR","slug":"oxybutynin-ir","indication":"Other","status":"marketed"},{"name":"timolol maleate 0.5%","genericName":"timolol maleate 0.5%","slug":"timolol-maleate-0-5","indication":"Other","status":"marketed"},{"name":"timolol ophthalmic solution","genericName":"timolol ophthalmic solution","slug":"timolol-ophthalmic-solution","indication":"Other","status":"marketed"}]},{"name":"Ophthalmology","slug":"ophthalmology","revenue":0,"percentOfTotal":0,"drugCount":24,"colorKey":"respiratory","drugs":[{"name":"Lubricating Eye Drop","genericName":"Lubricating Eye Drop","slug":"lubricating-eye-drop","indication":"Dry eye syndrome / Keratoconjunctivitis sicca","status":"marketed"},{"name":"REFRESH LIQUIGEL®","genericName":"REFRESH LIQUIGEL®","slug":"refresh-liquigel","indication":"Dry eye syndrome / keratoconjunctivitis sicca","status":"marketed"},{"name":"AGN-190584 ophthalmic solution","genericName":"AGN-190584 ophthalmic solution","slug":"agn-190584-ophthalmic-solution","indication":"Treatment of inflammation and pain in the eye","status":"phase_2"},{"name":"AGN-223575 ophthalmic solution","genericName":"AGN-223575 ophthalmic solution","slug":"agn-223575-ophthalmic-solution","indication":"Treatment of inflammation in the eye","status":"phase_2"},{"name":"AGN-229666","genericName":"AGN-229666","slug":"agn-229666","indication":"Dry eye disease","status":"phase_3"},{"name":"Artificial Tears REFRESH ENDURA®","genericName":"Artificial Tears REFRESH ENDURA®","slug":"artificial-tears-refresh-endura","indication":"Treatment of dry eye syndrome","status":"phase_2"},{"name":"Cyclosporine 0.010%","genericName":"Cyclosporine 0.010%","slug":"cyclosporine-0-010","indication":"Dry eye disease (keratoconjunctivitis sicca)","status":"phase_3"},{"name":"Cyclosporine Vehicle","genericName":"Cyclosporine Vehicle","slug":"cyclosporine-vehicle","indication":"Dry eye disease (keratoconjunctivitis sicca)","status":"phase_3"},{"name":"GoodSense Eye Drops Advanced Relief Moisturizer","genericName":"DEXTRAN","slug":"dextran","indication":"redness of the eye due to minor eye irritations","status":"marketed"},{"name":"Lubricant Eye Drops (Optive™)","genericName":"Lubricant Eye Drops (Optive™)","slug":"lubricant-eye-drops-optive","indication":"Dry eye disease / Keratoconjunctivitis sicca","status":"marketed"},{"name":"OPTIVE PLUS®","genericName":"OPTIVE PLUS®","slug":"optive-plus","indication":"Dry eye syndrome","status":"phase_2"},{"name":"Ophthalmic Emulsion","genericName":"Ophthalmic Emulsion","slug":"ophthalmic-emulsion","indication":"Dry eye disease / Keratoconjunctivitis sicca","status":"marketed"},{"name":"Pilocarpine HCl","genericName":"Pilocarpine HCl","slug":"pilocarpine-hcl","indication":"Xerostomia (dry mouth) in patients with Sjögren's syndrome","status":"phase_3"},{"name":"Systane Ultra Multidose","genericName":"Systane Ultra Multidose","slug":"systane-ultra-multidose","indication":"Relief of dryness and irritation associated with dry eye syndrome","status":"phase_3"},{"name":"Vehicle Ophthalmic Solution","genericName":"Vehicle Ophthalmic Solution","slug":"vehicle-ophthalmic-solution","indication":"Relief of dryness and irritation in the eyes","status":"phase_3"},{"name":"Vehicle Sterile Solution","genericName":"Vehicle Sterile Solution","slug":"vehicle-sterile-solution","indication":"Vehicle/control formulation for ophthalmic drug delivery","status":"marketed"},{"name":"botulinum toxin Type A (32U)","genericName":"botulinum toxin Type A (32U)","slug":"botulinum-toxin-type-a-32u","indication":"Focal spasm of eyelid (blepharospasm)","status":"phase_3"},{"name":"carboxymethylcellulose 0.5% +glycerin 0.9%","genericName":"carboxymethylcellulose 0.5% +glycerin 0.9%","slug":"carboxymethylcellulose-0-5-glycerin-0-9","indication":"Dry eye syndrome / keratoconjunctivitis sicca","status":"marketed"},{"name":"carboxymethylcellulose based eye drop formula","genericName":"carboxymethylcellulose based eye drop formula","slug":"carboxymethylcellulose-based-eye-drop-formula","indication":"Dry eye syndrome","status":"phase_3"},{"name":"carboxymethylcellulose sodium based Eye Drops","genericName":"carboxymethylcellulose sodium based Eye Drops","slug":"carboxymethylcellulose-sodium-based-eye-drops","indication":"Treatment of dry eye syndrome","status":"phase_3"},{"name":"carboxymethylcellulose-based lubricant eye drops","genericName":"carboxymethylcellulose-based lubricant eye drops","slug":"carboxymethylcellulose-based-lubricant-eye-drops","indication":"Dry eye disease / keratoconjunctivitis sicca","status":"marketed"},{"name":"hypromellose 0.3%","genericName":"hypromellose 0.3%","slug":"hypromellose-0-3","indication":"Dry eye disease / Keratoconjunctivitis sicca","status":"marketed"},{"name":"placebo eye drops","genericName":"placebo eye drops","slug":"placebo-eye-drops","indication":"Clinical trial control comparator","status":"marketed"},{"name":"sodium hyaluronate 0.18%","genericName":"sodium hyaluronate 0.18%","slug":"sodium-hyaluronate-0-18","indication":"Dry eye disease","status":"marketed"}]},{"name":"Cardiovascular","slug":"cardiovascular","revenue":0,"percentOfTotal":0,"drugCount":21,"colorKey":"immunology","drugs":[{"name":"Vehicle to bimatoprost solution","genericName":"Vehicle to bimatoprost solution","slug":"vehicle-to-bimatoprost-solution","indication":"Open-angle glaucoma","status":"phase_3"},{"name":"bimatoprost formulation A solution","genericName":"bimatoprost formulation A solution","slug":"bimatoprost-formulation-a-solution","indication":"Glaucoma","status":"phase_3"},{"name":"travatan 0.004%","genericName":"travatan 0.004%","slug":"travatan-0-004","indication":"Open-angle glaucoma","status":"marketed"},{"name":"vehicle of bimatoprost solution 0.03 %","genericName":"vehicle of bimatoprost solution 0.03 %","slug":"vehicle-of-bimatoprost-solution-0-03","indication":"Glaucoma","status":"phase_3"},{"name":"AGN-195263 0.1%","genericName":"AGN-195263 0.1%","slug":"agn-195263-0-1","indication":"Glaucoma","status":"phase_2"},{"name":"AGN-199201 ophthalmic solution","genericName":"AGN-199201 ophthalmic solution","slug":"agn-199201-ophthalmic-solution","indication":"Glaucoma or ocular hypertension (Phase 2)","status":"phase_2"},{"name":"Active Comparator: Timolol 0.5%","genericName":"Active Comparator: Timolol 0.5%","slug":"active-comparator-timolol-0-5","indication":"Glaucoma","status":"phase_3"},{"name":"Bimatoprost 0.01%","genericName":"Bimatoprost 0.01%","slug":"bimatoprost-0-01","indication":"Open-angle glaucoma","status":"marketed"},{"name":"Bimatoprost 0.03% sterile solution","genericName":"Bimatoprost 0.03% sterile solution","slug":"bimatoprost-0-03-sterile-solution","indication":"Open-angle glaucoma","status":"phase_3"},{"name":"Bimatoprost Ophthalmic Solution","genericName":"Bimatoprost Ophthalmic Solution","slug":"bimatoprost-ophthalmic-solution","indication":"Glaucoma","status":"marketed"},{"name":"Bimatoprost Solution 2","genericName":"Bimatoprost Solution 2","slug":"bimatoprost-solution-2","indication":"Glaucoma","status":"phase_2"},{"name":"Bimatoprost Vehicle","genericName":"Bimatoprost Vehicle","slug":"bimatoprost-vehicle","indication":"Open-angle glaucoma","status":"marketed"},{"name":"Bimatoprost cutaneous solution 0.03%","genericName":"Bimatoprost cutaneous solution 0.03%","slug":"bimatoprost-cutaneous-solution-0-03","indication":"Open-angle glaucoma","status":"phase_2"},{"name":"Brimonidine ophthalmic solution 0.1%","genericName":"Brimonidine ophthalmic solution 0.1%","slug":"brimonidine-ophthalmic-solution-0-1","indication":"Open-angle glaucoma","status":"marketed"},{"name":"Bystolic","genericName":"nebivolol","slug":"nebivolol","indication":"Hypertensive disorder","status":"marketed"},{"name":"Fixed Combination Bimatoprost and Timolol","genericName":"Fixed Combination Bimatoprost and Timolol","slug":"fixed-combination-bimatoprost-and-timolol","indication":"Glaucoma","status":"phase_2"},{"name":"Timolol Vehicle (placebo)","genericName":"Timolol Vehicle (placebo)","slug":"timolol-vehicle-placebo","indication":"Placebo control in clinical trials for glaucoma and ocular hypertension","status":"marketed"},{"name":"bimatoprost 0.03% ophthalmic solution","genericName":"bimatoprost 0.03% ophthalmic solution","slug":"bimatoprost-0-03-ophthalmic-solution","indication":"Open-angle glaucoma","status":"marketed"},{"name":"bimatoprost solution 0.03 %","genericName":"bimatoprost solution 0.03 %","slug":"bimatoprost-solution-0-03","indication":"Open-angle glaucoma","status":"phase_3"},{"name":"brimonidine 0.1% (Alphagan® P)","genericName":"brimonidine 0.1% (Alphagan® P)","slug":"brimonidine-0-1-alphagan-p","indication":"Open-angle glaucoma","status":"marketed"},{"name":"brimonidine tartrate ophthalmic solution","genericName":"brimonidine tartrate ophthalmic solution","slug":"brimonidine-tartrate-ophthalmic-solution","indication":"Open-angle glaucoma","status":"marketed"}]},{"name":"Infectious Disease","slug":"infectious-disease","revenue":0,"percentOfTotal":0,"drugCount":9,"colorKey":"pain","drugs":[{"name":"AGN-210669 ophthalmic solution, 0.05%","genericName":"AGN-210669 ophthalmic solution, 0.05%","slug":"agn-210669-ophthalmic-solution-0-05","indication":"Treatment of non-infectious uveitis affecting the posterior segment of the eye","status":"phase_2"},{"name":"AGN-210669 ophthalmic solution, 0.1%","genericName":"AGN-210669 ophthalmic solution, 0.1%","slug":"agn-210669-ophthalmic-solution-0-1","indication":"Treatment of noninfectious uveitis affecting the posterior segment of the eye","status":"phase_2"},{"name":"Ciprofloxacin 0.3% ophthalmic solution","genericName":"Ciprofloxacin 0.3% ophthalmic solution","slug":"ciprofloxacin-0-3-ophthalmic-solution","indication":"Treatment of bacterial conjunctivitis","status":"phase_2"},{"name":"Gatifloxacin 0.3% ophthalmic solution","genericName":"Gatifloxacin 0.3% ophthalmic solution","slug":"gatifloxacin-0-3-ophthalmic-solution","indication":"Bacterial conjunctivitis","status":"phase_2"},{"name":"Gatifloxacin 0.5% eye drops","genericName":"Gatifloxacin 0.5% eye drops","slug":"gatifloxacin-0-5-eye-drops","indication":"Bacterial conjunctivitis","status":"phase_3"},{"name":"Zymar","genericName":"GATIFLOXACIN","slug":"gatifloxacin","indication":"Acute bacterial sinusitis","status":"marketed"},{"name":"gatifloxacin ophthalmic solution 0.3%","genericName":"gatifloxacin ophthalmic solution 0.3%","slug":"gatifloxacin-ophthalmic-solution-0-3","indication":"Bacterial conjunctivitis","status":"marketed"},{"name":"moxifloxacin 0.5% HCI ophthalmic solution","genericName":"moxifloxacin 0.5% HCI ophthalmic solution","slug":"moxifloxacin-0-5-hci-ophthalmic-solution","indication":"Bacterial conjunctivitis","status":"marketed"},{"name":"moxifloxacin 0.5% eye drops","genericName":"moxifloxacin 0.5% eye drops","slug":"moxifloxacin-0-5-eye-drops","indication":"Bacterial conjunctivitis","status":"marketed"}]},{"name":"Dermatology","slug":"dermatology","revenue":0,"percentOfTotal":0,"drugCount":7,"colorKey":"infectious","drugs":[{"name":"Dapsone plus Adapalene","genericName":"Dapsone plus Adapalene","slug":"dapsone-plus-adapalene","indication":"Acne vulgaris","status":"marketed"},{"name":"ACZONE Gel, 5%","genericName":"ACZONE Gel, 5%","slug":"aczone-gel-5","indication":"Acne vulgaris","status":"marketed"},{"name":"Clindamycin/benzoyl peroxide plus Adapalene","genericName":"Clindamycin/benzoyl peroxide plus Adapalene","slug":"clindamycin-benzoyl-peroxide-plus-adapalene","indication":"Acne vulgaris","status":"marketed"},{"name":"Dapsone Topical Gel + adapalene gel 0.1%","genericName":"Dapsone Topical Gel + adapalene gel 0.1%","slug":"dapsone-topical-gel-adapalene-gel-0-1","indication":"Acne vulgaris","status":"phase_3"},{"name":"Dapsone Topical Gel + vehicle control","genericName":"Dapsone Topical Gel + vehicle control","slug":"dapsone-topical-gel-vehicle-control","indication":"Acne vulgaris","status":"phase_3"},{"name":"Dapsone; Tretinoin","genericName":"Dapsone; Tretinoin","slug":"dapsone-tretinoin","indication":"Acne vulgaris","status":"marketed"},{"name":"Vehicle to AGN-229666","genericName":"Vehicle to AGN-229666","slug":"vehicle-to-agn-229666","indication":"Inflammatory skin or ocular condition (specific indication not publicly confirmed)","status":"phase_3"}]},{"name":"Metabolic","slug":"metabolic","revenue":0,"percentOfTotal":0,"drugCount":4,"colorKey":"ophthalmology","drugs":[{"name":"AGN-195263 0.03%","genericName":"AGN-195263 0.03%","slug":"agn-195263-0-03","indication":"Type 2 diabetes","status":"phase_2"},{"name":"AGN-210961 Formulation 1","genericName":"AGN-210961 Formulation 1","slug":"agn-210961-formulation-1","indication":"Type 2 diabetes","status":"phase_2"},{"name":"AGN-210961 Formulation 5","genericName":"AGN-210961 Formulation 5","slug":"agn-210961-formulation-5","indication":"Hypercholesterolemia","status":"phase_2"},{"name":"AGN-210961 Formulation 7","genericName":"AGN-210961 Formulation 7","slug":"agn-210961-formulation-7","indication":"Hypercholesterolemia","status":"phase_2"}]},{"name":"Pain","slug":"pain","revenue":0,"percentOfTotal":0,"drugCount":2,"colorKey":"dermatology","drugs":[{"name":"AGN-210669","genericName":"AGN-210669","slug":"agn-210669","indication":"Chronic pain (specific indication under investigation in Phase 2)","status":"phase_2"},{"name":"ketorolac eye drops","genericName":"ketorolac eye drops","slug":"ketorolac-eye-drops","indication":"Ocular pain and inflammation","status":"phase_3"}]},{"name":"Immunology","slug":"immunology","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"neuroscience","drugs":[{"name":"DEX PS DDS®","genericName":"DEX PS DDS®","slug":"dex-ps-dds","indication":"Eczema","status":"phase_2"}]},{"name":"Oncology","slug":"oncology","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"rare","drugs":[{"name":"MAP0004","genericName":"MAP0004","slug":"map0004","indication":"Solid tumors (specific indication under investigation in Phase 3)","status":"phase_3"}]},{"name":"Rare Disease","slug":"rare-disease","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"metabolic","drugs":[{"name":"minoxidil 5% solution","genericName":"minoxidil 5% solution","slug":"minoxidil-5-solution","indication":"Androgenetic alopecia (male pattern baldness)","status":"marketed"}]}],"pipeline":[{"name":"Botox","genericName":"ONABOTULINUMTOXINA","slug":"onabotulinumtoxina","phase":"marketed","mechanism":"BOTOX blocks neuromuscular transmission by inhibiting acetylcholine release through cleavage of SNAP-25.","indications":["Overactive Bladder","Urinary Incontinence due to Detrusor Overactivity","Neurogenic Detrusor Overactivity","Chronic Migraine","Spasticity"],"catalyst":""},{"name":"Vehicle to bimatoprost solution","genericName":"Vehicle to bimatoprost solution","slug":"vehicle-to-bimatoprost-solution","phase":"phase_3","mechanism":"Bimatoprost is a prostaglandin F analog that increases uveoscleral outflow of aqueous humor to reduce intraocular pressure.","indications":["Open-angle glaucoma","Ocular hypertension"],"catalyst":""},{"name":"AGN211745","genericName":"AGN211745","slug":"agn211745","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"BELKYRA®","genericName":"BELKYRA®","slug":"belkyra","phase":"marketed","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Betaprone","genericName":"PROPIOLACTONE","slug":"propiolactone","phase":"marketed","mechanism":"Small molecule","indications":["Antiseptic preparation"],"catalyst":""},{"name":"Campral","genericName":"ACAMPROSATE","slug":"acamprosate","phase":"marketed","mechanism":"Campral works by modulating the activity of the GABA-A receptor, a key neurotransmitter system involved in regulating alcohol cravings and withdrawal symptoms.","indications":["Alcoholism"],"catalyst":""},{"name":"DEX PS DDS®","genericName":"DEX PS DDS®","slug":"dex-ps-dds","phase":"phase_2","mechanism":"DEX PS DDS is a corticosteroid used to reduce inflammation and suppress the immune system.","indications":["Eczema","Psoriasis"],"catalyst":""},{"name":"Dapsone plus Adapalene","genericName":"Dapsone plus Adapalene","slug":"dapsone-plus-adapalene","phase":"marketed","mechanism":"Dapsone reduces inflammation and bacterial growth while adapalene normalizes skin cell turnover and reduces sebum production, together targeting acne pathogenesis.","indications":["Acne vulgaris"],"catalyst":""},{"name":"Lubricating Eye Drop","genericName":"Lubricating Eye Drop","slug":"lubricating-eye-drop","phase":"marketed","mechanism":"Lubricating eye drops provide artificial tears that coat and moisturize the ocular surface to relieve dryness and irritation.","indications":["Dry eye syndrome / Keratoconjunctivitis sicca","Ocular irritation and discomfort"],"catalyst":""},{"name":"MAP0004","genericName":"MAP0004","slug":"map0004","phase":"phase_3","mechanism":"MAP0004 is a bispecific antibody that simultaneously engages two distinct molecular targets to enhance immune activation against cancer cells.","indications":["Solid tumors (specific indication under investigation in Phase 3)"],"catalyst":""},{"name":"REFRESH LIQUIGEL®","genericName":"REFRESH LIQUIGEL®","slug":"refresh-liquigel","phase":"marketed","mechanism":"REFRESH Liquigel provides ocular lubrication and protection by forming a viscous gel layer on the corneal surface to relieve dry eye symptoms.","indications":["Dry eye syndrome / keratoconjunctivitis sicca"],"catalyst":""},{"name":"Vehicle to AGN-199201","genericName":"Vehicle to AGN-199201","slug":"vehicle-to-agn-199201","phase":"phase_3","mechanism":"AGN-199201 is a selective antagonist of the neurokinin-1 (NK1) receptor that modulates pain signaling in the central nervous system.","indications":["Neuropathic pain","Chronic pain conditions"],"catalyst":""},{"name":"bimatoprost formulation A solution","genericName":"bimatoprost formulation A solution","slug":"bimatoprost-formulation-a-solution","phase":"phase_3","mechanism":"Bimatoprost is a prostaglandin analog that mimics the action of prostaglandin F2-alpha, leading to increased uveoscleral outflow and reduced intraocular pressure.","indications":["Glaucoma","Ocular hypertension"],"catalyst":""},{"name":"minoxidil 5% solution","genericName":"minoxidil 5% solution","slug":"minoxidil-5-solution","phase":"marketed","mechanism":"Minoxidil is a potassium channel opener that increases blood flow to hair follicles and prolongs the anagen (growth) phase of the hair cycle.","indications":["Androgenetic alopecia (male pattern baldness)","Female pattern hair loss"],"catalyst":""},{"name":"travatan 0.004%","genericName":"travatan 0.004%","slug":"travatan-0-004","phase":"marketed","mechanism":"Travoprost is a prostaglandin F analog that binds to prostaglandin F (FP) receptors to increase uveoscleral outflow of aqueous humor, thereby lowering intraocular pressure.","indications":["Open-angle glaucoma","Ocular hypertension"],"catalyst":""},{"name":"travoprost 0.004%","genericName":"travoprost 0.004%","slug":"travoprost-0-004","phase":"marketed","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"vehicle of bimatoprost solution 0.03 %","genericName":"vehicle of bimatoprost solution 0.03 %","slug":"vehicle-of-bimatoprost-solution-0-03","phase":"phase_3","mechanism":"Bimatoprost is a prostaglandin analog that mimics the action of prostaglandin F2-alpha, leading to increased uveoscleral outflow and decreased intraocular pressure.","indications":["Glaucoma","Ocular hypertension"],"catalyst":""},{"name":"0.15% Brimonidine Tartrate","genericName":"0.15% Brimonidine Tartrate","slug":"0-15-brimonidine-tartrate","phase":"marketed","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"ACZONE Gel, 5%","genericName":"ACZONE Gel, 5%","slug":"aczone-gel-5","phase":"marketed","mechanism":"Dapsone reduces inflammation and bacterial colonization in acne lesions through its antimicrobial and anti-inflammatory properties.","indications":["Acne vulgaris"],"catalyst":""},{"name":"AGN-150998","genericName":"AGN-150998","slug":"agn-150998","phase":"phase_2","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"AGN-190168 Formulation 1","genericName":"AGN-190168 Formulation 1","slug":"agn-190168-formulation-1","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"AGN-190168 Formulation 2","genericName":"AGN-190168 Formulation 2","slug":"agn-190168-formulation-2","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"AGN-190584","genericName":"AGN-190584","slug":"agn-190584","phase":"marketed","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"AGN-190584 ophthalmic solution","genericName":"AGN-190584 ophthalmic solution","slug":"agn-190584-ophthalmic-solution","phase":"phase_2","mechanism":"AGN-190584 ophthalmic solution is a corticosteroid used to treat inflammation in the eye.","indications":["Treatment of inflammation and pain in the eye"],"catalyst":""},{"name":"AGN-195263 0.01%","genericName":"AGN-195263 0.01%","slug":"agn-195263-0-01","phase":"phase_2","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"AGN-195263 0.03%","genericName":"AGN-195263 0.03%","slug":"agn-195263-0-03","phase":"phase_2","mechanism":"AGN-195263 is a glucagon receptor antagonist.","indications":["Type 2 diabetes"],"catalyst":""},{"name":"AGN-195263 0.1%","genericName":"AGN-195263 0.1%","slug":"agn-195263-0-1","phase":"phase_2","mechanism":"AGN-195263 is a topical ophthalmic agent that modulates intraocular pressure through enhanced aqueous humor outflow.","indications":["Glaucoma","Ocular hypertension"],"catalyst":""},{"name":"AGN-199201","genericName":"AGN-199201","slug":"agn-199201","phase":"phase_3","mechanism":"AGN-199201 is a selective androgen receptor modulator (SARM) that activates androgen signaling in target tissues.","indications":["Muscle wasting and weakness in aging males","Osteoporosis or bone loss"],"catalyst":""},{"name":"AGN-199201 Dose A","genericName":"AGN-199201 Dose A","slug":"agn-199201-dose-a","phase":"phase_2","mechanism":"AGN-199201 is a selective androgen receptor modulator (SARM) that activates androgen signaling in target tissues.","indications":["Muscle wasting or sarcopenia (phase 2 development)"],"catalyst":""},{"name":"AGN-199201 Dose B","genericName":"AGN-199201 Dose B","slug":"agn-199201-dose-b","phase":"phase_2","mechanism":"AGN-199201 Dose B is a drug that targets the molecular target to exert its therapeutic effect.","indications":[],"catalyst":""},{"name":"AGN-199201 Dose C","genericName":"AGN-199201 Dose C","slug":"agn-199201-dose-c","phase":"phase_2","mechanism":"AGN-199201 Dose C is a drug that targets the molecular target to exert its therapeutic effect.","indications":["Phase 2 clinical trials for AGN-199201 Dose C are ongoing, but no specific indications have been reported."],"catalyst":""},{"name":"AGN-199201 Formulation A","genericName":"AGN-199201 Formulation A","slug":"agn-199201-formulation-a","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"AGN-199201 Formulation B","genericName":"AGN-199201 Formulation B","slug":"agn-199201-formulation-b","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"AGN-199201 Formulation C","genericName":"AGN-199201 Formulation C","slug":"agn-199201-formulation-c","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"AGN-199201 ophthalmic solution","genericName":"AGN-199201 ophthalmic solution","slug":"agn-199201-ophthalmic-solution","phase":"phase_2","mechanism":"AGN-199201 is a selective prostaglandin F (FP) receptor agonist that increases uveoscleral outflow of aqueous humor to reduce intraocular pressure.","indications":["Glaucoma or ocular hypertension (Phase 2)"],"catalyst":""},{"name":"AGN-210669","genericName":"AGN-210669","slug":"agn-210669","phase":"phase_2","mechanism":"AGN-210669 is a selective inhibitor of the transient receptor potential vanilloid 1 (TRPV1) channel that reduces pain signaling in sensory neurons.","indications":["Chronic pain (specific indication under investigation in Phase 2)"],"catalyst":""},{"name":"AGN-210669 ophthalmic solution, 0.025%","genericName":"AGN-210669 ophthalmic solution, 0.025%","slug":"agn-210669-ophthalmic-solution-0-025","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"AGN-210669 ophthalmic solution, 0.05%","genericName":"AGN-210669 ophthalmic solution, 0.05%","slug":"agn-210669-ophthalmic-solution-0-05","phase":"phase_2","mechanism":"AGN-210669 ophthalmic solution is a corticosteroid used to reduce inflammation in the eye.","indications":["Treatment of non-infectious uveitis affecting the posterior segment of the eye"],"catalyst":""},{"name":"AGN-210669 ophthalmic solution, 0.075%","genericName":"AGN-210669 ophthalmic solution, 0.075%","slug":"agn-210669-ophthalmic-solution-0-075","phase":"phase_2","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"AGN-210669 ophthalmic solution, 0.1%","genericName":"AGN-210669 ophthalmic solution, 0.1%","slug":"agn-210669-ophthalmic-solution-0-1","phase":"phase_2","mechanism":"AGN-210669 ophthalmic solution is a corticosteroid used to reduce inflammation in the eye.","indications":["Treatment of noninfectious uveitis affecting the posterior segment of the eye"],"catalyst":""},{"name":"AGN-210961 Formulation 1","genericName":"AGN-210961 Formulation 1","slug":"agn-210961-formulation-1","phase":"phase_2","mechanism":"AGN-210961 is a small molecule targeting the SGLT2 receptor.","indications":["Type 2 diabetes"],"catalyst":""},{"name":"AGN-210961 Formulation 2","genericName":"AGN-210961 Formulation 2","slug":"agn-210961-formulation-2","phase":"phase_2","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"AGN-210961 Formulation 3","genericName":"AGN-210961 Formulation 3","slug":"agn-210961-formulation-3","phase":"phase_2","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"AGN-210961 Formulation 4","genericName":"AGN-210961 Formulation 4","slug":"agn-210961-formulation-4","phase":"phase_2","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"AGN-210961 Formulation 5","genericName":"AGN-210961 Formulation 5","slug":"agn-210961-formulation-5","phase":"phase_2","mechanism":"AGN-210961 Formulation 5 is a medication that targets the PCSK9 protein to lower LDL cholesterol.","indications":["Hypercholesterolemia"],"catalyst":""},{"name":"AGN-210961 Formulation 6","genericName":"AGN-210961 Formulation 6","slug":"agn-210961-formulation-6","phase":"phase_2","mechanism":"AGN-210961 is a selective androgen receptor modulator (SARM) designed to provide tissue-selective androgenic effects.","indications":["Muscle wasting or sarcopenia (investigational)","Bone health / osteoporosis (investigational)"],"catalyst":""},{"name":"AGN-210961 Formulation 7","genericName":"AGN-210961 Formulation 7","slug":"agn-210961-formulation-7","phase":"phase_2","mechanism":"AGN-210961 Formulation 7 is a drug that targets the PCSK9 protein to lower LDL cholesterol.","indications":["Hypercholesterolemia"],"catalyst":""},{"name":"AGN-223575 Formulation A","genericName":"AGN-223575 Formulation A","slug":"agn-223575-formulation-a","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"AGN-223575 Formulation B","genericName":"AGN-223575 Formulation B","slug":"agn-223575-formulation-b","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"AGN-223575 Formulation C","genericName":"AGN-223575 Formulation C","slug":"agn-223575-formulation-c","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"AGN-223575 ophthalmic solution","genericName":"AGN-223575 ophthalmic solution","slug":"agn-223575-ophthalmic-solution","phase":"phase_2","mechanism":"AGN-223575 ophthalmic solution is a corticosteroid used to treat inflammation in the eye.","indications":["Treatment of inflammation in the eye"],"catalyst":""},{"name":"AGN-229666","genericName":"AGN-229666","slug":"agn-229666","phase":"phase_3","mechanism":"AGN-229666 is a selective retinoid X receptor (RXR) agonist that modulates gene expression to reduce inflammation and promote tissue repair.","indications":["Dry eye disease","Meibomian gland dysfunction"],"catalyst":""},{"name":"AGN-232411","genericName":"AGN-232411","slug":"agn-232411","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"AGN208397 intravitreal injection","genericName":"AGN208397 intravitreal injection","slug":"agn208397-intravitreal-injection","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Active Comparator: Timolol 0.5%","genericName":"Active Comparator: Timolol 0.5%","slug":"active-comparator-timolol-0-5","phase":"phase_3","mechanism":"Timolol is a non-selective beta-adrenergic receptor antagonist that reduces intraocular pressure by decreasing aqueous humor production in the eye.","indications":["Glaucoma","Ocular hypertension"],"catalyst":""},{"name":"Alcaftadine 0.25%","genericName":"Alcaftadine 0.25%","slug":"alcaftadine-0-25","phase":"marketed","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Alcaftadine Ophthalmic Solution 0.25%","genericName":"Alcaftadine Ophthalmic Solution 0.25%","slug":"alcaftadine-ophthalmic-solution-0-25","phase":"phase_2","mechanism":"Antihistamine","indications":["Allergic conjunctivitis"],"catalyst":""},{"name":"Androderm®","genericName":"Androderm®","slug":"androderm","phase":"marketed","mechanism":"Androderm delivers testosterone transdermally to replace deficient testosterone in hypogonadal men.","indications":["Testosterone replacement therapy in adult males with primary or secondary hypogonadism"],"catalyst":""},{"name":"Any Fixed Combination Therapy","genericName":"Any Fixed Combination Therapy","slug":"any-fixed-combination-therapy","phase":"phase_2","mechanism":"This fixed combination therapy works by combining multiple drugs to treat various conditions.","indications":["Various conditions"],"catalyst":""},{"name":"Artificial Tears REFRESH ENDURA®","genericName":"Artificial Tears REFRESH ENDURA®","slug":"artificial-tears-refresh-endura","phase":"phase_2","mechanism":"REFRESH ENDURA artificial tears lubricate and protect the eyes by forming a thin layer on the surface of the eye.","indications":["Treatment of dry eye syndrome"],"catalyst":""},{"name":"BOTOX® purified neurotoxin complex","genericName":"BOTOX® purified neurotoxin complex","slug":"botox-purified-neurotoxin-complex","phase":"phase_2","mechanism":"Botulinum toxin type A inhibits acetylcholine release at the neuromuscular junction.","indications":["blepharospasm","strabismus","hemi-facial spasm","cervical dystonia","axillary hyperhidrosis"],"catalyst":""},{"name":"Bimatoprost 0.01%","genericName":"Bimatoprost 0.01%","slug":"bimatoprost-0-01","phase":"marketed","mechanism":"Bimatoprost is a prostaglandin F analog that binds to prostaglandin F receptors to increase uveoscleral outflow of aqueous humor, thereby reducing intraocular pressure.","indications":["Open-angle glaucoma","Ocular hypertension","Hypotrichosis of the eyelashes (eyelash growth)"],"catalyst":""},{"name":"Bimatoprost 0.03% sterile solution","genericName":"Bimatoprost 0.03% sterile solution","slug":"bimatoprost-0-03-sterile-solution","phase":"phase_3","mechanism":"Bimatoprost is a prostaglandin F analog that binds to prostaglandin F receptors to increase uveoscleral outflow of aqueous humor, thereby reducing intraocular pressure.","indications":["Open-angle glaucoma","Ocular hypertension","Hypotrichosis of the eyelashes"],"catalyst":""},{"name":"Bimatoprost Ophthalmic Solution","genericName":"Bimatoprost Ophthalmic Solution","slug":"bimatoprost-ophthalmic-solution","phase":"marketed","mechanism":"Bimatoprost is a prostaglandin F analog that binds to prostaglandin F receptors in the eye to increase uveoscleral outflow of aqueous humor, thereby lowering intraocular pressure.","indications":["Glaucoma","Ocular hypertension"],"catalyst":""},{"name":"Bimatoprost Ophthalmic Solution 0.01%","genericName":"Bimatoprost Ophthalmic Solution 0.01%","slug":"bimatoprost-ophthalmic-solution-0-01","phase":"marketed","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Bimatoprost Solution 2","genericName":"Bimatoprost Solution 2","slug":"bimatoprost-solution-2","phase":"phase_2","mechanism":"Prostaglandin F2α analogue","indications":["Glaucoma","Ocular hypertension"],"catalyst":""},{"name":"Bimatoprost Vehicle","genericName":"Bimatoprost Vehicle","slug":"bimatoprost-vehicle","phase":"marketed","mechanism":"Bimatoprost is a prostaglandin F analog that increases uveoscleral outflow of aqueous humor to reduce intraocular pressure.","indications":["Open-angle glaucoma","Ocular hypertension"],"catalyst":""},{"name":"Bimatoprost cutaneous solution 0.03%","genericName":"Bimatoprost cutaneous solution 0.03%","slug":"bimatoprost-cutaneous-solution-0-03","phase":"phase_2","mechanism":"Bimatoprost activates the prostaglandin F2 alpha receptor (FP receptor), leading to increased uveoscleral outflow of aqueous humor and reduced intraocular pressure.","indications":["Open-angle glaucoma","Ocular hypertension"],"catalyst":""},{"name":"Botox placebo (normal saline)","genericName":"Botox placebo (normal saline)","slug":"botox-placebo-normal-saline","phase":"phase_3","mechanism":"Normal saline is an inert placebo with no active pharmacological mechanism.","indications":["Placebo control in Botox clinical trials (Phase 3)"],"catalyst":""},{"name":"Botulinum Toxin Type A 150kDa","genericName":"Botulinum Toxin Type A 150kDa","slug":"botulinum-toxin-type-a-150kda","phase":"marketed","mechanism":"Biologic","indications":[],"catalyst":""},{"name":"Botulinum Toxin Type A 900kD","genericName":"Botulinum Toxin Type A 900kD","slug":"botulinum-toxin-type-a-900kd","phase":"marketed","mechanism":"Botulinum toxin type A blocks acetylcholine release at the neuromuscular junction by cleaving SNARE proteins, causing temporary muscle paralysis.","indications":["Cervical dystonia","Blepharospasm","Strabismus","Chronic migraine","Severe primary axillary hyperhidrosis"],"catalyst":""},{"name":"Botulinum Toxin Type A 900kDa","genericName":"Botulinum Toxin Type A 900kDa","slug":"botulinum-toxin-type-a-900kda","phase":"marketed","mechanism":"Botulinum toxin type A blocks acetylcholine release at the neuromuscular junction by cleaving SNARE proteins, causing temporary muscle paralysis.","indications":["Cervical dystonia","Blepharospasm","Strabismus","Chronic migraine","Severe primary axillary hyperhidrosis"],"catalyst":""},{"name":"Brimo PS DDS®","genericName":"Brimo PS DDS®","slug":"brimo-ps-dds","phase":"phase_2","mechanism":"Brimo PS DDS is a testosterone replacement therapy.","indications":["Treatment of hypogonadism in adult males"],"catalyst":""},{"name":"Brimonidine 0.2% ophthalmic solution","genericName":"Brimonidine 0.2% ophthalmic solution","slug":"brimonidine-0-2-ophthalmic-solution","phase":"marketed","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Brimonidine ophthalmic solution 0.1%","genericName":"Brimonidine ophthalmic solution 0.1%","slug":"brimonidine-ophthalmic-solution-0-1","phase":"marketed","mechanism":"Brimonidine is an alpha-2 adrenergic receptor agonist that reduces intraocular pressure by decreasing aqueous humor production and increasing uveoscleral outflow.","indications":["Open-angle glaucoma","Ocular hypertension"],"catalyst":""},{"name":"Bromanautine","genericName":"bromazine","slug":"bromazine","phase":"marketed","mechanism":"Histamine H1 receptor","indications":["Common cold","Cough","Nasal congestion","Nasal discharge"],"catalyst":""},{"name":"Bystolic","genericName":"nebivolol","slug":"nebivolol","phase":"marketed","mechanism":"5-hydroxytryptamine receptor 1A, Beta-1 adrenergic receptor, Beta-2 adrenergic receptor","indications":["Hypertensive disorder"],"catalyst":""},{"name":"Carboxymethylcellulose sodium and Glycerin","genericName":"Carboxymethylcellulose sodium and Glycerin","slug":"carboxymethylcellulose-sodium-and-glycerin","phase":"marketed","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Ciprofloxacin 0.3% ophthalmic solution","genericName":"Ciprofloxacin 0.3% ophthalmic solution","slug":"ciprofloxacin-0-3-ophthalmic-solution","phase":"phase_2","mechanism":"Ciprofloxacin 0.3% ophthalmic solution works by inhibiting bacterial DNA gyrase and topoisomerase IV, which are essential for bacterial DNA replication and transcription.","indications":["Treatment of bacterial conjunctivitis"],"catalyst":""},{"name":"Clindamycin/benzoyl peroxide plus Adapalene","genericName":"Clindamycin/benzoyl peroxide plus Adapalene","slug":"clindamycin-benzoyl-peroxide-plus-adapalene","phase":"marketed","mechanism":"This triple-combination topical treatment reduces acne through bacterial suppression (clindamycin), oxidative killing (benzoyl peroxide), and normalized skin cell turnover (adapalene).","indications":["Acne vulgaris"],"catalyst":""},{"name":"Cyclosporine 0.010%","genericName":"Cyclosporine 0.010%","slug":"cyclosporine-0-010","phase":"phase_3","mechanism":"Cyclosporine is a calcineurin inhibitor that suppresses T-cell activation and reduces inflammatory cytokine production in the eye.","indications":["Dry eye disease (keratoconjunctivitis sicca)"],"catalyst":""},{"name":"Cyclosporine 0.010% eye drops","genericName":"Cyclosporine 0.010% eye drops","slug":"cyclosporine-0-010-eye-drops","phase":"phase_2","mechanism":"Cyclosporine is an immunosuppressant that inhibits calcineurin, thereby reducing T-cell activation.","indications":["Prevention of organ rejection in transplant patients"],"catalyst":""},{"name":"Cyclosporine Vehicle","genericName":"Cyclosporine Vehicle","slug":"cyclosporine-vehicle","phase":"phase_3","mechanism":"Cyclosporine is an immunosuppressant that inhibits T-cell activation by blocking calcineurin, thereby reducing inflammatory responses in the eye.","indications":["Dry eye disease (keratoconjunctivitis sicca)","Ocular surface inflammation"],"catalyst":""},{"name":"Dapsone Topical Gel + adapalene gel 0.1%","genericName":"Dapsone Topical Gel + adapalene gel 0.1%","slug":"dapsone-topical-gel-adapalene-gel-0-1","phase":"phase_3","mechanism":"Dapsone provides antimicrobial and anti-inflammatory effects while adapalene is a retinoid that normalizes skin cell differentiation and reduces inflammation.","indications":["Acne vulgaris"],"catalyst":""},{"name":"Dapsone Topical Gel + vehicle control","genericName":"Dapsone Topical Gel + vehicle control","slug":"dapsone-topical-gel-vehicle-control","phase":"phase_3","mechanism":"Dapsone is a sulfone antimicrobial and anti-inflammatory agent that inhibits bacterial folate synthesis and suppresses neutrophil function to reduce inflammation in acne.","indications":["Acne vulgaris"],"catalyst":""},{"name":"Dapsone; Tretinoin","genericName":"Dapsone; Tretinoin","slug":"dapsone-tretinoin","phase":"marketed","mechanism":"This combination of dapsone (an antimicrobial and anti-inflammatory agent) and tretinoin (a retinoid that promotes skin cell turnover) works synergistically to reduce inflammation and normalize skin cell differentiation in acne and rosacea.","indications":["Acne vulgaris","Rosacea"],"catalyst":""},{"name":"Dexamethasone intravitreal implant","genericName":"Dexamethasone intravitreal implant","slug":"dexamethasone-intravitreal-implant","phase":"marketed","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Fixed Combination Bimatoprost and Timolol","genericName":"Fixed Combination Bimatoprost and Timolol","slug":"fixed-combination-bimatoprost-and-timolol","phase":"phase_2","mechanism":"Bimatoprost is a prostaglandin analog that lowers intraocular pressure by increasing uveoscleral outflow, while Timolol is a beta-adrenergic receptor blocker that reduces intraocular pressure by decreasing aqueous humor production.","indications":["Glaucoma","Ocular hypertension"],"catalyst":""},{"name":"Formulation C: OnabotulinumtoxinA","genericName":"Formulation C: OnabotulinumtoxinA","slug":"formulation-c-onabotulinumtoxina","phase":"phase_2","mechanism":"OnabotulinumtoxinA works by blocking the release of acetylcholine, a neurotransmitter that causes muscle contraction.","indications":["Blepharospasm","Cervical dystonia","Spasticity","Hemifacial spasm","Strabismus"],"catalyst":""},{"name":"Ganforti","genericName":"Ganforti","slug":"ganforti","phase":"phase_2","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Gatifloxacin 0.3% ophthalmic solution","genericName":"Gatifloxacin 0.3% ophthalmic solution","slug":"gatifloxacin-0-3-ophthalmic-solution","phase":"phase_2","mechanism":"Quinolone antibiotic that inhibits bacterial DNA gyrase and topoisomerase IV.","indications":["Bacterial conjunctivitis"],"catalyst":""},{"name":"Gatifloxacin 0.5% eye drops","genericName":"Gatifloxacin 0.5% eye drops","slug":"gatifloxacin-0-5-eye-drops","phase":"phase_3","mechanism":"Gatifloxacin is a fluoroquinolone antibiotic that inhibits bacterial DNA gyrase and topoisomerase IV, preventing bacterial DNA replication and transcription.","indications":["Bacterial conjunctivitis","Bacterial keratitis","Bacterial corneal ulcer"],"catalyst":""},{"name":"GoodSense Eye Drops Advanced Relief Moisturizer","genericName":"DEXTRAN","slug":"dextran","phase":"marketed","mechanism":"Oligosaccharide","indications":["redness of the eye due to minor eye irritations","further irritation","dryness of the eye"],"catalyst":""},{"name":"IV Placebo (Saline)","genericName":"IV Placebo (Saline)","slug":"iv-placebo-saline","phase":"marketed","mechanism":"IV saline placebo has no active pharmacological mechanism; it is a control comparator consisting of sterile sodium chloride solution.","indications":["Clinical trial control / placebo comparator (not a therapeutic indication)"],"catalyst":""},{"name":"Lubricant Eye Drops (Optive™)","genericName":"Lubricant Eye Drops (Optive™)","slug":"lubricant-eye-drops-optive","phase":"marketed","mechanism":"Optive lubricates and protects the ocular surface by providing a multi-component tear substitute that mimics natural tears.","indications":["Dry eye disease / Keratoconjunctivitis sicca","Ocular surface lubrication and protection"],"catalyst":""},{"name":"OPTIVE PLUS®","genericName":"OPTIVE PLUS®","slug":"optive-plus","phase":"phase_2","mechanism":"OPTIVE PLUS® contains sodium hyaluronate and polyethylene glycol, which work together to lubricate and protect the ocular surface.","indications":["Dry eye syndrome"],"catalyst":""},{"name":"Ophthalmic Emulsion","genericName":"Ophthalmic Emulsion","slug":"ophthalmic-emulsion","phase":"marketed","mechanism":"An ophthalmic emulsion that lubricates and protects the ocular surface by providing moisture and forming a protective barrier on the cornea and conjunctiva.","indications":["Dry eye disease / Keratoconjunctivitis sicca"],"catalyst":""},{"name":"Oxymetazoline HCL Cream 1.0%","genericName":"Oxymetazoline HCL Cream 1.0%","slug":"oxymetazoline-hcl-cream-1-0","phase":"marketed","mechanism":"Oxymetazoline is an alpha-1 adrenergic agonist that causes vasoconstriction of blood vessels in the skin, reducing redness and flushing.","indications":["Persistent facial erythema associated with rosacea"],"catalyst":""},{"name":"Pilocarpine HCl","genericName":"Pilocarpine HCl","slug":"pilocarpine-hcl","phase":"phase_3","mechanism":"Pilocarpine HCl is a muscarinic acetylcholine receptor agonist that stimulates parasympathetic activity to increase salivary and lacrimal gland secretion.","indications":["Xerostomia (dry mouth) in patients with Sjögren's syndrome","Xerophthalmia (dry eyes)","Radiation-induced xerostomia"],"catalyst":""},{"name":"Placebo-matching Ubrogepant","genericName":"Placebo-matching Ubrogepant","slug":"placebo-matching-ubrogepant","phase":"phase_3","mechanism":"Ubrogepant is a calcitonin gene-related peptide receptor antagonist.","indications":["Acute treatment of migraine attacks with or without aura","Prevention of migraine attacks"],"catalyst":""},{"name":"Systane Ultra Multidose","genericName":"Systane Ultra Multidose","slug":"systane-ultra-multidose","phase":"phase_3","mechanism":"Systane Ultra Multidose lubricates the eyes to help relieve dryness and irritation.","indications":["Relief of dryness and irritation associated with dry eye syndrome"],"catalyst":""},{"name":"Timolol Vehicle (placebo)","genericName":"Timolol Vehicle (placebo)","slug":"timolol-vehicle-placebo","phase":"marketed","mechanism":"This is a placebo vehicle formulation with no active pharmacological mechanism.","indications":["Placebo control in clinical trials for glaucoma and ocular hypertension"],"catalyst":""},{"name":"Ulipristal acetate (UPA)","genericName":"Ulipristal acetate (UPA)","slug":"ulipristal-acetate-upa","phase":"phase_3","mechanism":"Ulipristal acetate acts as a selective progesterone receptor modulator (SPRM) to prevent ovulation and thicken cervical mucus, thereby inhibiting sperm penetration.","indications":["Emergency contraception","Treatment of moderate to severe symptoms of uterine fibroids"],"catalyst":""},{"name":"Vehicle Ophthalmic Solution","genericName":"Vehicle Ophthalmic Solution","slug":"vehicle-ophthalmic-solution","phase":"phase_3","mechanism":"Vehicle ophthalmic solution is a clear liquid used to lubricate the eyes.","indications":["Relief of dryness and irritation in the eyes"],"catalyst":""},{"name":"Vehicle Sterile Solution","genericName":"Vehicle Sterile Solution","slug":"vehicle-sterile-solution","phase":"marketed","mechanism":"Vehicle Sterile Solution is an inert carrier formulation used as a control or diluent in ophthalmic drug delivery systems.","indications":["Vehicle/control formulation for ophthalmic drug delivery"],"catalyst":""},{"name":"Vehicle to AGN-229666","genericName":"Vehicle to AGN-229666","slug":"vehicle-to-agn-229666","phase":"phase_3","mechanism":"AGN-229666 is a selective retinoid X receptor (RXR) agonist that modulates nuclear receptor signaling to reduce inflammation and promote tissue repair.","indications":["Inflammatory skin or ocular condition (specific indication not publicly confirmed)"],"catalyst":""},{"name":"Vehicle to Oxymetazoline HCL Cream","genericName":"Vehicle to Oxymetazoline HCL Cream","slug":"vehicle-to-oxymetazoline-hcl-cream","phase":"phase_3","mechanism":"Oxymetazoline HCL is a selective alpha-1 adrenergic agonist that constricts blood vessels in the skin to reduce facial redness and erythema.","indications":["Persistent facial erythema associated with rosacea"],"catalyst":""},{"name":"Zymar","genericName":"GATIFLOXACIN","slug":"gatifloxacin","phase":"marketed","mechanism":"DNA gyrase, DNA gyrase, DNA gyrase subunit A","indications":["Acute bacterial sinusitis","Acute exacerbation of chronic bronchitis","Acute gonococcal cervicitis","Acute gonococcal urethritis","Bacterial conjunctivitis"],"catalyst":""},{"name":"alcaftadine 0.25% ophthalmic solution","genericName":"alcaftadine 0.25% ophthalmic solution","slug":"alcaftadine-0-25-ophthalmic-solution","phase":"marketed","mechanism":"Alcaftadine is a selective H1-receptor antagonist that blocks histamine-mediated allergic responses in the eye.","indications":["Allergic conjunctivitis (itching associated with allergic conjunctivitis)"],"catalyst":""},{"name":"bimatoprost 0.01% ophthalmic solution","genericName":"bimatoprost 0.01% ophthalmic solution","slug":"bimatoprost-0-01-ophthalmic-solution","phase":"marketed","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"bimatoprost 0.03% eye drops","genericName":"bimatoprost 0.03% eye drops","slug":"bimatoprost-0-03-eye-drops","phase":"marketed","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"bimatoprost 0.03% ophthalmic solution","genericName":"bimatoprost 0.03% ophthalmic solution","slug":"bimatoprost-0-03-ophthalmic-solution","phase":"marketed","mechanism":"Bimatoprost is a prostaglandin F analog that binds to prostaglandin F receptors in the eye to increase uveoscleral outflow of aqueous humor, thereby lowering intraocular pressure.","indications":["Open-angle glaucoma","Ocular hypertension"],"catalyst":""},{"name":"bimatoprost 0.03% plus timolol 0.5%","genericName":"bimatoprost 0.03% plus timolol 0.5%","slug":"bimatoprost-0-03-plus-timolol-0-5","phase":"marketed","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"bimatoprost ophthalmic solution 0.03%","genericName":"bimatoprost ophthalmic solution 0.03%","slug":"bimatoprost-ophthalmic-solution-0-03","phase":"marketed","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"bimatoprost solution 0.03 %","genericName":"bimatoprost solution 0.03 %","slug":"bimatoprost-solution-0-03","phase":"phase_3","mechanism":"Bimatoprost is a prostaglandin F analog that binds to prostaglandin F receptors to increase uveoscleral outflow of aqueous humor, thereby reducing intraocular pressure.","indications":["Open-angle glaucoma","Ocular hypertension","Hypotrichosis of the eyelashes"],"catalyst":""},{"name":"botulinum toxin Type A (12 U)","genericName":"botulinum toxin Type A (12 U)","slug":"botulinum-toxin-type-a-12-u","phase":"phase_3","mechanism":"Botulinum toxin Type A works by blocking the release of acetylcholine, a neurotransmitter that causes muscle contraction.","indications":[],"catalyst":""},{"name":"botulinum toxin Type A (24 U)","genericName":"botulinum toxin Type A (24 U)","slug":"botulinum-toxin-type-a-24-u","phase":"phase_3","mechanism":"Botulinum toxin Type A works by blocking the release of acetylcholine, a neurotransmitter that causes muscle contraction.","indications":["Focal spasticity in patients with upper limb spasticity due to stroke or cerebral palsy","Severe primary axillary hyperhidrosis"],"catalyst":""},{"name":"botulinum toxin Type A (300U)","genericName":"botulinum toxin Type A (300U)","slug":"botulinum-toxin-type-a-300u","phase":"phase_3","mechanism":"Botulinum toxin Type A works by blocking the release of acetylcholine, a neurotransmitter that causes muscle contraction.","indications":[],"catalyst":""},{"name":"botulinum toxin Type A (32U)","genericName":"botulinum toxin Type A (32U)","slug":"botulinum-toxin-type-a-32u","phase":"phase_3","mechanism":"Botulinum toxin Type A (32U) works by blocking the release of acetylcholine, a neurotransmitter that causes muscle contraction.","indications":["Focal spasm of eyelid (blepharospasm)","Strabismus","Cervical dystonia","Hemifacial spasm","Severe primary axillary hyperhidrosis"],"catalyst":""},{"name":"botulinum toxin Type A (44U)","genericName":"botulinum toxin Type A (44U)","slug":"botulinum-toxin-type-a-44u","phase":"phase_3","mechanism":"Botulinum toxin Type A (44U) works by blocking the release of acetylcholine, a neurotransmitter that causes muscle contraction.","indications":["Focal spasticity in patients with upper limb spasticity due to stroke or cerebral palsy","Cervical dystonia"],"catalyst":""},{"name":"brimonidine 0.1% (Alphagan® P)","genericName":"brimonidine 0.1% (Alphagan® P)","slug":"brimonidine-0-1-alphagan-p","phase":"marketed","mechanism":"Brimonidine is an alpha-2 adrenergic receptor agonist that reduces intraocular pressure by decreasing aqueous humor production and increasing uveoscleral outflow in the eye.","indications":["Open-angle glaucoma","Ocular hypertension"],"catalyst":""},{"name":"brimonidine tartrate ophthalmic solution","genericName":"brimonidine tartrate ophthalmic solution","slug":"brimonidine-tartrate-ophthalmic-solution","phase":"marketed","mechanism":"Brimonidine tartrate is an alpha-2 adrenergic receptor agonist that reduces intraocular pressure by decreasing aqueous humor production and increasing uveoscleral outflow.","indications":["Open-angle glaucoma","Ocular hypertension"],"catalyst":""},{"name":"carboxymethylcellulose 0.5% +glycerin 0.9%","genericName":"carboxymethylcellulose 0.5% +glycerin 0.9%","slug":"carboxymethylcellulose-0-5-glycerin-0-9","phase":"marketed","mechanism":"Carboxymethylcellulose and glycerin work together to lubricate and hydrate the ocular surface, providing relief from dry eye symptoms.","indications":["Dry eye syndrome / keratoconjunctivitis sicca"],"catalyst":""},{"name":"carboxymethylcellulose based eye drop formula","genericName":"carboxymethylcellulose based eye drop formula","slug":"carboxymethylcellulose-based-eye-drop-formula","phase":"phase_3","mechanism":"Carboxymethylcellulose based eye drops act as artificial tears to lubricate and moisten the eye, providing relief from dryness and irritation.","indications":["Dry eye syndrome"],"catalyst":""},{"name":"carboxymethylcellulose sodium based Eye Drops","genericName":"carboxymethylcellulose sodium based Eye Drops","slug":"carboxymethylcellulose-sodium-based-eye-drops","phase":"phase_3","mechanism":"Carboxymethylcellulose sodium eye drops work by forming a protective barrier on the surface of the eye to help soothe and lubricate dry eyes.","indications":["Treatment of dry eye syndrome"],"catalyst":""},{"name":"carboxymethylcellulose-based lubricant eye drops","genericName":"carboxymethylcellulose-based lubricant eye drops","slug":"carboxymethylcellulose-based-lubricant-eye-drops","phase":"marketed","mechanism":"Carboxymethylcellulose acts as a viscous lubricant that coats and protects the ocular surface, mimicking natural tears to relieve dryness and irritation.","indications":["Dry eye disease / keratoconjunctivitis sicca","Ocular surface irritation and discomfort"],"catalyst":""},{"name":"cyclosporine 0.05% ophthalmic emulsion","genericName":"cyclosporine 0.05% ophthalmic emulsion","slug":"cyclosporine-0-05-ophthalmic-emulsion","phase":"marketed","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"gatifloxacin ophthalmic solution 0.3%","genericName":"gatifloxacin ophthalmic solution 0.3%","slug":"gatifloxacin-ophthalmic-solution-0-3","phase":"marketed","mechanism":"Gatifloxacin is a fluoroquinolone antibiotic that inhibits bacterial DNA gyrase and topoisomerase IV, preventing bacterial DNA replication and transcription.","indications":["Bacterial conjunctivitis","Bacterial corneal ulcers","Other bacterial ocular infections"],"catalyst":""},{"name":"hypromellose 0.3%","genericName":"hypromellose 0.3%","slug":"hypromellose-0-3","phase":"marketed","mechanism":"Hypromellose is a cellulose-based polymer that forms a protective lubricating film on the ocular surface to relieve dry eye symptoms.","indications":["Dry eye disease / Keratoconjunctivitis sicca","Ocular irritation and discomfort"],"catalyst":""},{"name":"ketorolac eye drops","genericName":"ketorolac eye drops","slug":"ketorolac-eye-drops","phase":"phase_3","mechanism":"Ketorolac eye drops work by reducing inflammation and pain in the eye by inhibiting prostaglandin synthesis.","indications":["Ocular pain and inflammation"],"catalyst":""},{"name":"latanoprost 0.005%","genericName":"latanoprost 0.005%","slug":"latanoprost-0-005","phase":"marketed","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"latanoprost 0.005% eye drops","genericName":"latanoprost 0.005% eye drops","slug":"latanoprost-0-005-eye-drops","phase":"marketed","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"minoxidil 2% solution","genericName":"minoxidil 2% solution","slug":"minoxidil-2-solution","phase":"marketed","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"moxifloxacin 0.5% HCI ophthalmic solution","genericName":"moxifloxacin 0.5% HCI ophthalmic solution","slug":"moxifloxacin-0-5-hci-ophthalmic-solution","phase":"marketed","mechanism":"Moxifloxacin is a fluoroquinolone antibiotic that inhibits bacterial DNA gyrase and topoisomerase IV, preventing DNA replication and causing bacterial cell death.","indications":["Bacterial conjunctivitis","Bacterial corneal ulcer","Prophylaxis of bacterial infection following ocular surgery"],"catalyst":""},{"name":"moxifloxacin 0.5% eye drops","genericName":"moxifloxacin 0.5% eye drops","slug":"moxifloxacin-0-5-eye-drops","phase":"marketed","mechanism":"Moxifloxacin is a fluoroquinolone antibiotic that inhibits bacterial DNA gyrase and topoisomerase IV, preventing bacterial DNA replication and transcription.","indications":["Bacterial conjunctivitis","Bacterial keratitis","Bacterial corneal ulcer","Post-operative ocular infection prophylaxis"],"catalyst":""},{"name":"olopatadine 0.2% ophthalmic solution","genericName":"olopatadine 0.2% ophthalmic solution","slug":"olopatadine-0-2-ophthalmic-solution","phase":"marketed","mechanism":"Olopatadine blocks H1-receptors on ocular mast cells and other immune cells to reduce histamine-mediated itching and allergic inflammation in the eye.","indications":["Allergic conjunctivitis (ocular itching associated with allergies)"],"catalyst":""},{"name":"onabotulinumtoxinA 24 U","genericName":"onabotulinumtoxinA 24 U","slug":"onabotulinumtoxina-24-u","phase":"phase_3","mechanism":"onabotulinumtoxinA 24 U works by temporarily paralyzing muscles to treat muscle spasms and other conditions.","indications":[],"catalyst":""},{"name":"onabotulinumtoxinA 44 U","genericName":"onabotulinumtoxinA 44 U","slug":"onabotulinumtoxina-44-u","phase":"phase_3","mechanism":"onabotulinumtoxinA 44 U works by temporarily paralyzing muscles to treat various conditions.","indications":["Blepharospasm","Strabismus","Cervical dystonia","Hemifacial spasm","Spasticity"],"catalyst":""},{"name":"oxybutynin IR","genericName":"oxybutynin IR","slug":"oxybutynin-ir","phase":"marketed","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"placebo eye drops","genericName":"placebo eye drops","slug":"placebo-eye-drops","phase":"marketed","mechanism":"Placebo eye drops contain no active pharmaceutical ingredient and produce therapeutic effects solely through the placebo effect.","indications":["Clinical trial control comparator","Dry eye symptoms (placebo-responsive patients)"],"catalyst":""},{"name":"sodium hyaluronate 0.18%","genericName":"sodium hyaluronate 0.18%","slug":"sodium-hyaluronate-0-18","phase":"marketed","mechanism":"Sodium hyaluronate is a viscoelastic substance that lubricates and protects the ocular surface by mimicking natural tear film.","indications":["Dry eye disease","Ocular surface protection during ophthalmic surgery"],"catalyst":""},{"name":"timolol maleate 0.5%","genericName":"timolol maleate 0.5%","slug":"timolol-maleate-0-5","phase":"marketed","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"timolol ophthalmic solution","genericName":"timolol ophthalmic solution","slug":"timolol-ophthalmic-solution","phase":"marketed","mechanism":"Small molecule","indications":[],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMiygFBVV95cUxNdXJ2ajNLM3N1VmhSc2JiLWNRUDhpRE5nYm0zV1FuakVuQllIUjdfZUxNeVBQNlBIejB0NTViNDhzN05uZUVscElOalJNVlJiR3h4UUR3MnB4b19VLUt0MmJFc0JTbTdZTE1KSWdyOURoWFVZQzZ3dGxuaXlBeVpYdTVJX2xCZi05Z1dpbUxnRDFNZm1TMzQwTTVnenZLV1p0cW9sLXZsNjhBcF85QURnaDg4Uy1rMGUyNFJSaTR4aDBPa0tzNEdGMFVB?oc=5","date":"2026-02-24","type":"deal","source":"thecurrency.news","summary":"From $12bn IP deal to $11.6bn payout: How AbbVie’s Irish arm availed of a lucrative tax loop - thecurrency.news","headline":"From $12bn IP deal to $11.6bn payout: How AbbVie’s Irish arm availed of a lucrative tax loop","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMicEFVX3lxTE1SUVY3VmlYaUdGSXZyQ1hId2tDOWhRU0E4YzZ5T3B3UTU5RlRIcEJ1cVQtbnNTNExnY1dPdlNOeTcwbWpxVzV1V3BPUGZ0Y1RGNDhRX3dVYzdFZEpxUEEtYkY0RGFSVERYdFpSYVBqMzQ?oc=5","date":"2026-02-19","type":"earnings","source":"Statista","summary":"Revenue of Allergan plc from 2012 to 2019 - Statista","headline":"Revenue of Allergan plc from 2012 to 2019","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMikgFBVV95cUxPcGVSSGIyVE1tcEJaWU9xLXFWbERoWVFpY1Y4ZmRPbGYtUC1rZG1mUFJZeXVOVHhpal81R1IzaHNIemYwSGM5dFItdFltRFg5b1VmQXB0OFRWNEFHQ0VOLUJUZzVpTkM2M0xsckRJOFFyTlJUQjRRUDVLN0p1QUs0WTkyUW02VExKaTJjODc0WUFQZw?oc=5","date":"2026-02-18","type":"pipeline","source":"Yahoo Finance","summary":"A Look At Tarsus Pharmaceuticals (TARS) Valuation After Adding Former Allergan CEO David Pyott To Its Board - Yahoo Finance","headline":"A Look At Tarsus Pharmaceuticals (TARS) Valuation After Adding Former Allergan CEO David Pyott To Its Board","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi-wFBVV95cUxQcG1qT1k5UUlwVWoySHB4dmw5UlEtX1h0QTVVQTk4VmN6RDRLc3dxaDJURnBJTXFQX2pvRHpaYzZXMkRET3o3TG9pVDVPZ3UxNTR3S092TTlDWllFMjlvV0xlZVNXWGIyb1M1WnVpd2VRTTQ1MzZhNmhtVWU5dUJzejFIQVRpc0FFX2dxNnUtandBaXJwT0lNb2hhb1dXQWtGRFJLMFA1WHFlWkY5MjhwR05mMzc0WE5nb2Etbng4c1ZhbkJ1cGRId282UEEwbEhCX3R5dG9hV3VEYkJjWl96cGFfSGVyNDdzTVBiRHJYMFBIXzVDZENJbWhmWQ?oc=5","date":"2026-02-18","type":"pipeline","source":"BioSpace","summary":"Tarsus Pharmaceuticals Appoints Renowned Biopharmaceutical Leader and Former Allergan CEO, David Pyott, to its Board of Directors - BioSpace","headline":"Tarsus Pharmaceuticals Appoints Renowned Biopharmaceutical Leader and Former Allergan CEO, David Pyott, to its Board of ","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiggFBVV95cUxQdVFBaWc5YzRNdkFsbEl2anBTekVMaV9zbVJodDYtdWNiQUJEMEtDamRLeDRYaE42Q2hac2ZTR3dYZnExU1o2allHUkF1OEMtV1FyZWZxc2Zia0dSOG1sY1hENEk1NTl5dnc0eThiZVgzQzdOd3FlQllWNE9OVlNHeFRn?oc=5","date":"2025-11-29","type":"pipeline","source":"Statista","summary":"Total global sales of Allergan's Botox in 2017 and forecasted for 2024 - Statista","headline":"Total global sales of Allergan's Botox in 2017 and forecasted for 2024","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMibkFVX3lxTE10VUVCdnFDeksyQk03SHM2alZyZ2VneUUtVmpxWDdoRlZJekVCWF9Pa0JVTlkzc1FObWVkT1lYVkxJSFhtYkRRMjNhSDM2UlZxOTF4bWJTTzVXWWRfNkVIdXRPSlkwSmI2OVJKMzJ30gFyQVVfeXFMT0d2RTNFbThPN0trU2oyQnBOZWItbnNXZV9jdnZ2TUVsRE8tNl9lbEtUaGpXZVIydTlPMURzMTk1c1FkQmRIdGxTYzVueVpQNzYtdTlFZ3ktUlJ0VlVBd011ZTgybXhyRDRZNTBEQ3ZrZjln?oc=5","date":"2025-10-14","type":"pipeline","source":"koreabiomed.com","summary":"Hugel names ex-Allergan Aesthetics chief Carrie Strom as global CEO - koreabiomed.com","headline":"Hugel names ex-Allergan Aesthetics chief Carrie Strom as global CEO","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMipwFBVV95cUxOSFQ4bUhxaE9reVBrMDZQSlBudlpUQzJObnZiN1J1VmFaMjFDNjc4VVcybFc3ZW9icTVITG1TeVR4M24yQ2puM1hUMGpqaVFTRGxVUllSSFBLNnZuQ2xreWVvOFVLeFFmbS02dlBRcjBWOFk4SmhJdmdCU1RQb3ZnaWtEWXJmb0Zwbjljc2UyeWJVdW1XSGJyOXBHMkFWNlQ4UmdaWVBodw?oc=5","date":"2025-07-22","type":"patent","source":"Fierce Pharma","summary":"AbbVie wins $56M royalty award from Revance in Botox patent infringement case - Fierce Pharma","headline":"AbbVie wins $56M royalty award from Revance in Botox patent infringement case","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMipwFBVV95cUxQZWRid3VmU0poLUQwWEhQM2hDTXJrOEY2b0JPTnMwXzJ4LWdKdmduY2lYOXB6ZmFha2JVSkI0SFJycDRpd21IMmUwUHFCc2VVNFMzeTJRV1I1VlAtNkQ1Y05QQ3NJVjc5bzNLb3QwV1haR1VCMXFLWXdiU2JUT0R2cU5NWkJPbEFpMHkwNTMzU1M4eDBSU282MWxaSVg3MVgtdTFmd2syMA?oc=5","date":"2025-05-27","type":"pipeline","source":"Fierce Pharma","summary":"AbbVie's Allergan Aesthetics unit plots 202 layoffs after recent sales slide - Fierce Pharma","headline":"AbbVie's Allergan Aesthetics unit plots 202 layoffs after recent sales slide","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiqgFBVV95cUxNRm1vNXFNXzk2TzNud3gtUDdwcThmREhMNVJWWndwLW5kcVB0OWZRVWhCS3dOQndhWlgzaXpjeE5ZUG5MOTA0RS1YT2pfTkNZMXI1WUNvcUVQOWdRWlNFRnBRQkktNzZVTXZoZnJpcTlzZmpHcHdtMlZzZFRaR0tYbHhfeTl2Wmo1Ym1XbGp6cWZQdXdoN3FLUXJTcHNBcHN3ajJnbTRkVmIwUQ?oc=5","date":"2019-06-26","type":"pipeline","source":"BioPharma Dive","summary":"5 reasons AbbVie bought Allergan, and why they may not be enough - BioPharma Dive","headline":"5 reasons AbbVie bought Allergan, and why they may not be enough","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMirgFBVV95cUxOTGt5S2RVdDlyRXE0c282UFNOek00cHpWeDBZWlJWT1pVZkU2cFJrMDlaMVJoYTd3ZEF1REpyaXdaNlhQUXF4TTY4M2QtU0dnMjFxekhwU3dFeGhyVWd0bHl6S2VtWVJlaGtSWENwM2pYLXIySVdUMzBwc1Q1TGRMZkFRRlZoVTV5WEtyQms5T3hXa2R5aUljUkFtc1UzWkQzRDFzaWpiUC1vRWRjc3c?oc=5","date":"2019-06-25","type":"deal","source":"statnews.com","summary":"AbbVie to acquire Allergan for $63 billion in megamerger of pharma giants - statnews.com","headline":"AbbVie to acquire Allergan for $63 billion in megamerger of pharma giants","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiXkFVX3lxTFB1SF9JTGRkQ3p0UGlvTjE3TkM1SWNyVXR0c1FjLS1XV1FzNzZTcTU5YkMtMWxUa0RmOFY5YnVhaGFDMUlrNzBOTDQ3WEtJWm9aeU9oR1RWbkRkMlpDZUE?oc=5","date":"2018-08-08","type":"pipeline","source":"Drugwatch.com","summary":"Allergan – History, Products, Recalls, Lawsuits & Other Facts - Drugwatch.com","headline":"Allergan – History, Products, Recalls, Lawsuits & Other Facts","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi-wFBVV95cUxQMDF0WThvc1hZdHNoakJoekVhOURuLUltdURwSFdEMjJJMDI0aGlEQTVVRGVack4xNmVjNFlDS3dJMUZIZzZhX0lhbTdkZ2VlVk5GNl8tY1QxM3lUNzRxX191OUp4R1huOExQNm9oc3JaeUpZU2RNQTJpMnVDN2t1M2t5cDhuczlObXVmdW5raXZxVERSMkN5OTBoMFY5VGdidTNveW5WQmJ6M3BJeXlXWjF3MmxYVTlZMmtrQzJQMWstdExpd2dvZkVZcGJPaXhCeldRNzJPVWpwTEp6ZE9UcVkzMW1HNHhtWmE0MVZLRkFJdE5qci1ndHJtUQ?oc=5","date":"2016-11-22","type":"deal","source":"prnewswire.com","summary":"Allergan Acquires Chase Pharmaceuticals to Expand CNS R&D Pipeline and Build on Commitment to Alzheimer's Disease - prnewswire.com","headline":"Allergan Acquires Chase Pharmaceuticals to Expand CNS R&D Pipeline and Build on Commitment to Alzheimer's Disease","sentiment":"neutral"}],"patents":[],"drugCount":143,"phaseCounts":{"marketed":62,"phase_3":33,"phase_1":12,"phase_2":36},"enrichmentLevel":2,"visitCount":1,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}